A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Inclusion Criteria:

- Be male or female adults, 18 years of age or older

- Have SBS that is inadequately controlled on current antidiarrheal medication (e.g.,
loperamide or diphenoxylate), including subjects with ileostomies

- Must have been deemed a completer of study protocol MP-101-CL-001.

- Males or non-pregnant, non-lactating females who are postmenopausal, naturally or
surgically sterile, or who agree to use effective contraceptive methods throughout
the course of the study. Postmenopausal is defined as at least 12 months of natural
spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral
oophorectomy)

- Females of childbearing potential must agree to use 1 of the following acceptable
birth control methods:

- Surgically sterile (hysterectomy or bilateral oophorectomy)

- Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior
to study initiation)

- Intrauterine device (IUD) in place for at least 3 months

- Abstinence (not having sexual intercourse)

- Barrier method (condom or diaphragm) with spermicide for at least 14 days prior
to screening and through study completion

- Stable hormonal contraceptive for at least 3 months prior to study and through
study completion

- Vasectomized partner

- Females of childbearing potential must have a negative serum human chorionic
gonadotropin (hCG) pregnancy test at Visit 1.

- Be able to understand and provide signed informed consent

Exclusion Criteria:

- Have any history of or active neurological, endocrine, cardiovascular, pulmonary,
hematological, immunologic, psychiatric, or metabolic disease that is considered
clinically significant, is not currently controlled by medication, and is stable as
deemed by the Investigator

- Are currently taking antibiotics for bacterial overgrowth

- Have known or suspected pregnancy, planned pregnancy, or lactation

- Have a planned surgery during the course of the study

- Have a condition the Investigator believes would interfere with the ability to
provide informed consent or comply with study instructions, or that might confound
the interpretation of the study results or put the subject at undue risk